Changes in Quality of Life in Treatment-Resistant Schizophrenia Patients Undergoing Avatar Therapy: A Content Analysis

Overview

Journal J Pers Med

Date 2023 Mar 29

PMID 36983704

Authors

Melissa Beaudoin

Stephane Potvin

Kingsada Phraxayavong

Alexandre Dumais

Affiliations

Soon will be listed here.

Abstract

Avatar Therapy has a significant impact on symptoms, beliefs, and quality of life of patients with treatment-resistant schizophrenia. However, little is known about how these changes are implemented into their lives and to which aspects of their lives these improvements relate. Ten consecutive patients enrolled in an ongoing clinical trial were assessed using semi-guided interviews before as well as three months after Avatar Therapy. These encounters have been recorded and transcribed so that the discourse could be thoroughly analyzed, leading to the generation of an extensive theme grid. As the cases were analyzed, the grid was adapted in a back-and-forth manner until data saturation occurred. The content analysis allowed the identification of nine main themes representing different aspects of the patients' lives, each of which was subdivided into more specific codes. By analyzing the evolution of their frequency, it was observed that, following therapy, patients presented with fewer psychotic symptoms, better self-esteem, more hobbies and projects, and an overall improved lifestyle and mood. Finally, investigating the impact of Avatar Therapy on quality of life allows for a deeper understanding of how people with treatment-resistant schizophrenia can achieve meaningful changes and move towards a certain recovery process.

Citing Articles

Enhancing Predictive Power: Integrating a Linear Support Vector Classifier with Logistic Regression for Patient Outcome Prognosis in Virtual Reality Therapy for Treatment-Resistant Schizophrenia.

Hudon A, Beaudoin M, Phraxayavong K, Potvin S, Dumais A J Pers Med. 2023; 13(12).

PMID: 38138887 PMC: 10744538. DOI: 10.3390/jpm13121660.

References

Rathee R, Luhrmann T, Bhatia T, Deshpande S . Cognitive insight and objective quality of life in people with schizophrenia and auditory hallucinations. Psychiatry Res. 2017; 259:223-228. PMC: 5758479. DOI: 10.1016/j.psychres.2017.09.032. View

Karow A, Schafer I, Hirdes F, Osterwald C, Naber D . [Subjective view of positive symptoms and quality of life in patients with schizophrenia]. Psychiatr Prax. 2008; 35(6):286-93. DOI: 10.1055/s-2007-986385. View

Beaudoin M, Hudon A, Giguere C, Potvin S, Dumais A . Prediction of quality of life in schizophrenia using machine learning models on data from Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. Schizophrenia (Heidelb). 2022; 8(1):29. PMC: 8938459. DOI: 10.1038/s41537-022-00236-w. View

Ritsner M, Kurs R, Gibel A, Ratner Y, Endicott J . Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients. Qual Life Res. 2005; 14(7):1693-703. DOI: 10.1007/s11136-005-2816-9. View

Stepnicki P, Kondej M, Kaczor A . Current Concepts and Treatments of Schizophrenia. Molecules. 2018; 23(8). PMC: 6222385. DOI: 10.3390/molecules23082087. View

Nathou C, Etard O, Dollfus S . Auditory verbal hallucinations in schizophrenia: current perspectives in brain stimulation treatments. Neuropsychiatr Dis Treat. 2019; 15:2105-2117. PMC: 6662171. DOI: 10.2147/NDT.S168801. View

Nieuwdorp W, Koops S, Somers M, Sommer I . Transcranial magnetic stimulation, transcranial direct current stimulation and electroconvulsive therapy for medication-resistant psychosis of schizophrenia. Curr Opin Psychiatry. 2015; 28(3):222-8. DOI: 10.1097/YCO.0000000000000156. View

Howes O, McCutcheon R, Agid O, de Bartolomeis A, van Beveren N, Birnbaum M . Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry. 2016; 174(3):216-229. PMC: 6231547. DOI: 10.1176/appi.ajp.2016.16050503. View

Fortgang R, Hoff R, Potenza M . Schizophrenia symptom severity and motivations for gambling in individuals with schizophrenia or schizoaffective disorder. Psychiatry Res. 2020; 291:113281. DOI: 10.1016/j.psychres.2020.113281. View

10.

Campana M, Falkai P, Siskind D, Hasan A, Wagner E . Characteristics and definitions of ultra-treatment-resistant schizophrenia - A systematic review and meta-analysis. Schizophr Res. 2021; 228:218-226. DOI: 10.1016/j.schres.2020.12.002. View

11.

Petkari E, Pietschnig J . Associations of Quality of Life with Service Satisfaction in Psychotic Patients: A Meta-Analysis. PLoS One. 2015; 10(8):e0135267. PMC: 4537198. DOI: 10.1371/journal.pone.0135267. View

12.

Desalegn D, Girma S, Abdeta T . Quality of life and its association with psychiatric symptoms and socio-demographic characteristics among people with schizophrenia: A hospital-based cross-sectional study. PLoS One. 2020; 15(2):e0229514. PMC: 7039432. DOI: 10.1371/journal.pone.0229514. View

13.

Smith B, Fowler D, Freeman D, Bebbington P, Bashforth H, Garety P . Emotion and psychosis: links between depression, self-esteem, negative schematic beliefs and delusions and hallucinations. Schizophr Res. 2006; 86(1-3):181-8. DOI: 10.1016/j.schres.2006.06.018. View

14.

Mohan M, Perry B, Saravanan P, Singh S . COVID-19 in People With Schizophrenia: Potential Mechanisms Linking Schizophrenia to Poor Prognosis. Front Psychiatry. 2021; 12:666067. PMC: 8166317. DOI: 10.3389/fpsyt.2021.666067. View

15.

Watson P, Zhang J, Rizvi A, Tamaiev J, Birnbaum M, Kane J . A meta-analysis of factors associated with quality of life in first episode psychosis. Schizophr Res. 2018; 202:26-36. DOI: 10.1016/j.schres.2018.07.013. View

16.

Percie du Sert O, Potvin S, Lipp O, Dellazizzo L, Laurelli M, Breton R . Virtual reality therapy for refractory auditory verbal hallucinations in schizophrenia: A pilot clinical trial. Schizophr Res. 2018; 197:176-181. DOI: 10.1016/j.schres.2018.02.031. View

17.

Kozloff N, Mulsant B, Stergiopoulos V, Voineskos A . The COVID-19 Global Pandemic: Implications for People With Schizophrenia and Related Disorders. Schizophr Bull. 2020; 46(4):752-757. PMC: 7197583. DOI: 10.1093/schbul/sbaa051. View

18.

Kumari R, Chaudhury S, Kumar S . Dimensions of hallucinations and delusions in affective and nonaffective illnesses. ISRN Psychiatry. 2013; 2013:616304. PMC: 3755384. DOI: 10.1155/2013/616304. View

19.

Connell J, OCathain A, Brazier J . Measuring quality of life in mental health: are we asking the right questions?. Soc Sci Med. 2014; 120:12-20. PMC: 4224500. DOI: 10.1016/j.socscimed.2014.08.026. View

20.

Lins L, Carvalho F . SF-36 total score as a single measure of health-related quality of life: Scoping review. SAGE Open Med. 2016; 4:2050312116671725. PMC: 5052926. DOI: 10.1177/2050312116671725. View